Merck’s Wnt Agonist Is Efficacious As New Mechanism For Eye Disease

发布时间：2026-09-26 17:59

Remigromig showed non-inferiority to Lucentis in a Phase IIb/III trial in diabetic macular edema, but with higher rates of safety issues.